Screening and treating Helicobacter pylori infection for gastric cancer prevention on the population level
Authors:
- 30 May 2017
- journal article
- review article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 32 (6) , 1160-1169
Abstract
Helicobacter pylori infection is the major cause of gastric cancer, and removal of H. pylori infection from a population could theoretically decrease the number of cases by about 89%. However, in real‐life settings, few studies have reported the effect of screening and treating this pathogen in population‐based programs. This is mainly because of the lack of an adequate infrastructure for delivery of systematic screening services to asymptomatic individuals, the lack of standardization to ensure that each subject receives the correct diagnostic testing and antibiotic treatment, and limited resources. We illustrate our method of implementing two population‐based screen‐and‐treat programs in Taiwan, where the epidemiological characteristics of disease burden have changed from the traditionally Eastern pattern towards that of the Western countries. Our first example is a high‐risk population that resides on an offshore island, in which a strategy of mass eradication of H. pylori was applied. The other example is an intermediate‐risk population, which is representative of the general average‐risk population, in which there is integration of the screen‐and‐treat method with the established framework of colorectal cancer screening using the fecal‐occult blood test. The information provided here may be useful for integration of gastric cancer prevention measures into the healthcare priorities of populations with different gastric cancer risks, such as those with limited resources.Keywords
This publication has 64 references indexed in Scilit:
- Accuracy of faecal occult blood test andHelicobacter pyloristool antigen test for detection of upper gastrointestinal lesionsBMJ Open, 2013
- The benefit of mass eradication ofHelicobacter pyloriinfection: a community-based study of gastric cancer preventionGut, 2012
- Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancerGastrointestinal Endoscopy, 2012
- Gastric cancers in Finnish patients after cure of Helicobacter pylori infection: A cohort studyInternational Journal of Cancer, 2010
- Nonsteroidal Antiinflammatory Drugs and Risk of Gastric Adenocarcinoma: The Multiethnic Cohort StudyAmerican Journal of Epidemiology, 2009
- Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysisBritish Journal of Cancer, 2009
- Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trialThe Lancet, 2008
- Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseasesJournal of Gastroenterology, 2007
- Macrolide resistance in the normal microbiota after Helicobacter pylori treatmentScandinavian Journal of Infectious Diseases, 2007
- Low-Dose Aspirin in the Primary Prevention of CancerJAMA, 2005